Learn how breathing strategies and cold immersion techniques developed by Wim Hof directly impact the autonomic and ...

A significant percentage of patients with RA and ANCA positivity were also diagnosed with AAV, with GPA being the most common subtype.

Final results from the RA-BEYOND study show that patients with rheumatoid arthritis can often maintain disease control after tapering baricitinib from 4 mg to 2 mg.

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Adverse drug reactions are more common in the liver than in the kidneys for patients with rheumatoid arthritis using ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The following is a summary of “Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study,” published in the April ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Patients with RA who achieve LDA with certolizumab plus methotrexate had similar rates of worsening symptoms following either ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

The recombinant zoster vaccine protects against HZ and PHN in older patients with RA, with no increased risk for RA flares found within 30 days of vaccination.

The long-term incidence of MACE, VTE, and malignancies is low among patients with RA or UC receiving filgotinib, though a slight increase was observed among older patients.